Literature DB >> 19248136

Perception of improvement in patients with rheumatoid arthritis varies with disease activity levels at baseline.

D Aletaha1, J Funovits, M M Ward, J S Smolen, T K Kvien.   

Abstract

OBJECTIVE: To analyze the minimum clinically important improvement (MCII) of disease activity measures in rheumatoid arthritis (RA) using patient-derived anchors, and to assess whether criteria for improvement differ with baseline disease activity.
METHODS: We used data from a Norwegian observational database comprising 1,050 patients (73% women, 65% rheumatoid factor-positive, mean duration of RA 7.7 years). At 3 months after initiation of therapy, patients indicated whether their condition had improved, had considerably improved, was unchanged, had worsened, or had considerably worsened. We used receiver operating characteristic curve analysis to determine the MCII for the Disease Activity Score based on the assessment of 28 joints (DAS28), the Simplified Disease Activity Index (SDAI), and the Clinical Disease Activity Index (CDAI), and analyzed the effects of different levels of baseline disease activity on the MCII.
RESULTS: On average, patients started with high disease activity and improved significantly during treatment (American College of Rheumatology 20%, 50%, and 70% improvement criteria responses were 37%, 17%, and 5%, respectively). The overall mean (95% confidence interval [95% CI]) thresholds for MCII after 3 months for the DAS28, SDAI, and CDAI were 1.20 (95% CI 1.18-1.22), 10.95 (95% CI 10.69-11.20), and 10.76 (95% CI 10.49-11.04), respectively, and the mean (95% CI) thresholds for major responses were 1.82 (95% CI 1.80-1.83), 15.82 (95% CI 15.65-16.00), and 15.00 (95% CI 14.82-15.18), respectively. With increasing disease activity, much higher changes in disease activity were needed to achieve MCII according to patient judgment.
CONCLUSION: The perception of improvement of disease activity of patients with RA is considerably different depending on the disease activity level at which they start.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19248136      PMCID: PMC2957836          DOI: 10.1002/art.24282

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  28 in total

1.  Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score.

Authors:  D M van der Heijde; M A van 't Hof; P L van Riel; L A Theunisse; E W Lubberts; M A van Leeuwen; M H van Rijswijk; L B van de Putte
Journal:  Ann Rheum Dis       Date:  1990-11       Impact factor: 19.103

2.  Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo. The Cooperative Systematic Studies of Rheumatic Diseases Group.

Authors:  H E Paulus; M J Egger; J R Ward; H J Williams
Journal:  Arthritis Rheum       Date:  1990-04

3.  A methodological framework to develop and select indices for clinical trials: statistical and judgmental approaches.

Authors:  C Bombardier; P Tugwell
Journal:  J Rheumatol       Date:  1982 Sep-Oct       Impact factor: 4.666

4.  Validity of single variables and composite indices for measuring disease activity in rheumatoid arthritis.

Authors:  D M van der Heijde; M A van't Hof; P L van Riel; M A van Leeuwen; M H van Rijswijk; L B van de Putte
Journal:  Ann Rheum Dis       Date:  1992-02       Impact factor: 19.103

5.  A simplified disease activity index for rheumatoid arthritis for use in clinical practice.

Authors:  J S Smolen; F C Breedveld; M H Schiff; J R Kalden; P Emery; G Eberl; P L van Riel; P Tugwell
Journal:  Rheumatology (Oxford)       Date:  2003-02       Impact factor: 7.580

6.  Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial.

Authors:  Catriona Grigor; Hilary Capell; Anne Stirling; Alex D McMahon; Peter Lock; Ramsay Vallance; Wilma Kincaid; Duncan Porter
Journal:  Lancet       Date:  2004 Jul 17-23       Impact factor: 79.321

7.  Interpretation and power of a pooled index.

Authors:  C H Goldsmith; H A Smythe; A Helewa
Journal:  J Rheumatol       Date:  1993-03       Impact factor: 4.666

8.  Interrelationship of outcome measures and process variables in early rheumatoid arthritis. A comparison of radiologic damage, physical disability, joint counts, and acute phase reactants.

Authors:  M A van Leeuwen; D M van der Heijde; M H van Rijswijk; P M Houtman; P L van Riel; L B van de Putte; P C Limburg
Journal:  J Rheumatol       Date:  1994-03       Impact factor: 4.666

9.  The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials.

Authors:  D T Felson; J J Anderson; M Boers; C Bombardier; M Chernoff; B Fried; D Furst; C Goldsmith; S Kieszak; R Lightfoot
Journal:  Arthritis Rheum       Date:  1993-06

10.  Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations.

Authors:  D Aletaha; R Landewe; T Karonitsch; J Bathon; M Boers; C Bombardier; S Bombardieri; H Choi; B Combe; M Dougados; P Emery; J Gomez-Reino; E Keystone; G Koch; T K Kvien; E Martin-Mola; M Matucci-Cerinic; K Michaud; J O'Dell; H Paulus; T Pincus; P Richards; L Simon; J Siegel; J S Smolen; T Sokka; V Strand; P Tugwell; D van der Heijde; P van Riel; S Vlad; R van Vollenhoven; M Ward; M Weinblatt; G Wells; B White; F Wolfe; B Zhang; A Zink; D Felson
Journal:  Arthritis Rheum       Date:  2008-10-15
View more
  22 in total

1.  Individual patient monitoring in daily clinical practice: a critical evaluation of minimal important change.

Authors:  Jos Hendrikx; Jaap Fransen; Wietske Kievit; Piet L C M van Riel
Journal:  Qual Life Res       Date:  2014-09-25       Impact factor: 4.147

2.  Association of socioeconomic status with treatment delays, disease activity, joint damage, and disability in rheumatoid arthritis.

Authors:  Emily Molina; Inmaculada Del Rincon; Jose Felix Restrepo; Daniel F Battafarano; Agustin Escalante
Journal:  Arthritis Care Res (Hoboken)       Date:  2015-07       Impact factor: 4.794

3.  A Prospective Evaluation of the Effects of Prevalent Depressive Symptoms on Disease Activity in Rheumatoid Arthritis Patients Treated With Biologic Response Modifiers.

Authors:  Alan M Rathbun; Leslie R Harrold; George W Reed
Journal:  Clin Ther       Date:  2016-06-29       Impact factor: 3.393

4.  Determinants of discordance in patients' and physicians' rating of rheumatoid arthritis disease activity.

Authors:  Nasim A Khan; Horace J Spencer; Esam Abda; Amita Aggarwal; Rieke Alten; Codrina Ancuta; Daina Andersone; Martin Bergman; Jurgen Craig-Muller; Jacqueline Detert; Lia Georgescu; Laure Gossec; Hisham Hamoud; Johannes W G Jacobs; Ieda Maria Magalhaes Laurindo; Maria Majdan; Antonio Naranjo; Sapan Pandya; Christof Pohl; Georg Schett; Zahraa I Selim; Sergio Toloza; Hisahi Yamanaka; Tuulikki Sokka
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-02       Impact factor: 4.794

5.  Clinically important changes in individual and composite measures of rheumatoid arthritis activity: thresholds applicable in clinical trials.

Authors:  Michael M Ward; Lori C Guthrie; Maria I Alba
Journal:  Ann Rheum Dis       Date:  2014-05-01       Impact factor: 19.103

6.  Determining the Minimally Important Difference in the Clinical Disease Activity Index for Improvement and Worsening in Early Rheumatoid Arthritis Patients.

Authors:  J R Curtis; S Yang; L Chen; J E Pope; E C Keystone; B Haraoui; G Boire; J C Thorne; D Tin; C A Hitchon; C O Bingham; V P Bykerk
Journal:  Arthritis Care Res (Hoboken)       Date:  2015-10       Impact factor: 4.794

7.  Estimates of minimal clinically important improvments vary with the responsiveness of the sample.

Authors:  Michael M Ward; Maria I Alba
Journal:  J Clin Epidemiol       Date:  2021-11-06       Impact factor: 6.437

8.  Dependence of the minimal clinically important improvement on the baseline value is a consequence of floor and ceiling effects and not different expectations by patients.

Authors:  Michael M Ward; Lori C Guthrie; Maria Alba
Journal:  J Clin Epidemiol       Date:  2014-02-17       Impact factor: 6.437

Review 9.  [Rheumatoid arthritis. Target outcome for treatment].

Authors:  D Aletaha; J Smolen
Journal:  Z Rheumatol       Date:  2009-02       Impact factor: 1.372

10.  Increased disease activity in early arthritis patients with anti-carbamylated protein antibodies.

Authors:  Cristina Regueiro; Laura Nuño; Ana Triguero-Martinez; Ana M Ortiz; Alejandro Villalba; María Dolores Bóveda; Ana Martínez-Feito; Carmen Conde; Alejandro Balsa; Isidoro González-Alvaro; Antonio Gonzalez
Journal:  Sci Rep       Date:  2021-05-11       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.